Nevertheless, in melanoma and bladder cancer, even patients with tumors that are negative or low for PDL-1 expression derive some level of clinical benefit from anti-PD-1/PDL-1 inhibitors. The gene discussed is CD274; the disease is urinary bladder cancer.